Delcath Systems To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 13, 2017
11 March 2017 - 12:30AM
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology
Company focused on the treatment of primary and metastatic liver
cancers, today announced that Jennifer K. Simpson, Ph.D., MSN,
CRNP, President and Chief Executive Officer of Delcath will be a
featured presenter at the ROTH Capital Partners 29th Annual Growth
Stock Conference on Monday, March 13, 2017 at 7:30 AM Pacific Time
in BLUE - SALON 2 at the Ritz-Carlton Laguna Niguel, CA.
Dr. Simpson will highlight the recent corporate
developments and provide an overview of the Company.
A live webcast of the presentation will be available at
http://delcath.com/investors-events/ and a webcast replay will
be available at the same address approximately one hour after the
live webcast presentation for 90 days. Please log in approximately
5-10 minutes before the event to ensure a timely connection.
Management will be available for one-on-one
meetings with investors throughout the conference.
About Delcath Systems
Delcath Systems, Inc. is an interventional
oncology Company focused on the treatment of primary and metastatic
liver cancers. Our investigational product—Melphalan Hydrochloride
for Injection for use with the Delcath Hepatic Delivery System
(Melphalan/HDS) —is designed to administer high-dose chemotherapy
to the liver while controlling systemic exposure and associated
side effects. We have commenced a global Phase 3 FOCUS clinical
trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and a
global Phase 2 clinical trial in Europe and the U.S. to
investigate the Melphalan/HDS system for the treatment of primary
liver cancer (HCC) and intrahepatic cholangiocarcinoma (ICC).
Melphalan/HDS has not been approved by the U.S. Food & Drug
Administration (FDA) for sale in the U.S. In Europe, our
system has been commercially available since 2012 under the trade
name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan
(CHEMOSAT), where it has been used at major medical centers to
treat a wide range of cancers of the liver.
Forward-Looking Statements:
Private Securities Litigation Reform Act of 1995
provides a safe harbor for forward-looking statements made by the
Company or on its behalf. This news release contains
forward-looking statements, which are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating
to: our ability to repay and comply with the obligations under
our senior secured convertible notes, the timing and results of the
Company's clinical trials including without limitation the
OM, HCC, and ICC clinical trial programs, timely
enrollment and treatment of patients in the global Phase 3 FOCUS
Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma
and the global Phase 2 HCC and ICC clinical trials, IRB or ethics
committee clearance of the Phase 2 HCC/ICC and/or Phase 3
OM protocols from participating sites and the timing of
site activation and subject enrollment in each trial, the impact,
if any, of publication of the Phase 3 trial manuscript to support
the Company's efforts, the impact of the presentations at major
medical conferences and future clinical results consistent with the
data presented, the impact, if any of ZE reimbursement on
potential CHEMOSAT product use and sales in Germany, clinical
adoption, use and resulting sales, if any, for the CHEMOSAT system
to deliver and filter melphalan in Europe, the Company's ability to
successfully commercialize the CHEMOSAT/Melphalan HDS system and
the potential of the CHEMOSAT/Melphalan HDS system as a treatment
for patients with primary and metastatic disease in the liver, our
ability to obtain reimbursement for the CHEMOSAT system in various
markets, the Company's ability to satisfy the remaining
requirements of the FDA's Complete Response Letter and provide the
same in a timely manner, approval of the current or future
Melphalan HDS/CHEMOSAT system for delivery and filtration of
melphalan for various indications in the U.S. and/or in foreign
markets, actions by the FDA or other foreign regulatory agencies,
the Company's ability to successfully enter into strategic
partnership and distribution arrangements in foreign markets and
the timing and revenue, if any, of the same, uncertainties relating
to the timing and results of research and development projects, our
ability to maintain NASDAQ listing, and uncertainties regarding the
Company's ability to obtain financial and other resources for any
research, development, clinical trials and commercialization
activities. These factors, and others, are discussed from time to
time in our filings with the Securities and Exchange Commission.
You should not place undue reliance on these forward-looking
statements, which speak only as of the date they are made. We
undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after
the date they are made.
Contact Information:
David Boral
Managing Director
CORE IR
Tel: 516 222 2560
Email: davidb@coreir.com